Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00279
|
|||||
| Drug Name |
Canagliflozin
|
|||||
| Synonyms |
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; 6S49DGR869; 842133-18-0; 928672-86-0; CHEBI:73274; Canagliflozin anhydrous; Canagliflozin hydrate; Invokana; JNJ 24831754ZAE; JNJ-28431754; TA 7284; TA-7284; UNII-6S49DGR869; canagliflozin hemihydrate
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Type 2 diabetes [ICD11: 5A11] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C24H25FO5S
|
|||||
| Canonical SMILES |
CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
|
|||||
| InChI |
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
|
|||||
| InChIKey |
XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
|
|||||
| CAS Number |
CAS 842133-18-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 444.5 | Topological Polar Surface Area | 118 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
3.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
125299338
, 134358471
, 135267033
, 136023439
, 136340353
, 136367529
, 136368011
, 141631822
, 144115779
, 144224573
, 152159581
, 152258221
, 160647057
, 160695863
, 160865968
, 162011557
, 162169318
, 162205127
, 164837687
, 170500828
, 172918748
, 174530759
, 175266021
, 175427146
, 178101303
, 185964359
, 196373210
, 198993774
, 202567714
, 211535181
, 223258907
, 223471388
, 223617458
, 223705166
, 224378424
, 226521104
, 248537044
, 249737173
, 250163176
, 252109951
, 252215091
, 49811874
, 57127075
|
|||||
| ChEBI ID |
CHEBI:73274
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | ||
| References | ||||||
| 1 | Canagliflozin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.